2013
Physiologic Frailty and Fragility Fracture in HIV-Infected Male Veterans
Womack JA, Goulet JL, Gibert C, Brandt CA, Skanderson M, Gulanski B, Rimland D, Rodriguez-Barradas MC, Tate J, Yin MT, Justice AC, Team F. Physiologic Frailty and Fragility Fracture in HIV-Infected Male Veterans. Clinical Infectious Diseases 2013, 56: 1498-1504. PMID: 23378285, PMCID: PMC3634308, DOI: 10.1093/cid/cit056.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusVACS Index scoreFragility fracturesPhysiologic frailtyVACS IndexMale veteransInhibitor useFracture riskRisk factorsVeterans Aging Cohort Study (VACS) IndexIndex scoreFragility fracture risk factorsICD-9-CM codesProtease inhibitor useFracture risk factorsMarkers of inflammationBody mass indexUpper arm fracturesAlcohol-related diagnosesCox regression modelFirst fragility fractureCause mortalityHIV RNAHemoglobin levelsMass index
2011
Increased Risk of Fragility Fractures among HIV Infected Compared to Uninfected Male Veterans
Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, Fraenkel L, Mattocks K, Rimland D, Rodriguez-Barradas MC, Tate J, Yin MT, Justice AC, . Increased Risk of Fragility Fractures among HIV Infected Compared to Uninfected Male Veterans. PLOS ONE 2011, 6: e17217. PMID: 21359191, PMCID: PMC3040233, DOI: 10.1371/journal.pone.0017217.Peer-Reviewed Original ResearchConceptsBody mass indexHIV infectionUninfected menFragility fracturesFracture riskRisk factorsMale veteransVeterans Aging Cohort Study Virtual CohortCurrent protease inhibitor useFragility fracture risk factorsMedian body mass indexHIV-specific factorsAdjusted hazard ratioProtease inhibitor useFracture risk factorsFragility fracture riskIncident hipHazard ratioInhibitor useUnadjusted riskHIV statusMass indexAlcohol abuseHIVUpper arm
2004
Disease progression in HIV-infected patients treated with stavudine vs. zidovudine
Justice AC, Stein DS, Fusco GP, Sherrill BH, Fusco JS, Danehower SC, Becker SL, Hansen NI, Graham NM, Team T. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine. Journal Of Clinical Epidemiology 2004, 57: 89-97. PMID: 15019015, DOI: 10.1016/s0895-4356(03)00245-2.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAnti-HIV AgentsAntiretroviral Therapy, Highly ActiveDatabases, FactualDisease ProgressionDisease-Free SurvivalFollow-Up StudiesHIV InfectionsHIV Wasting SyndromeHumansProportional Hazards ModelsProspective StudiesReverse Transcriptase InhibitorsStavudineZidovudineConceptsCells/microLDisease progressionLandmark analysisCox proportional hazards modelEvent-free survivalHIV-1 patientsHIV-1 RNAProportional hazards modelPrevious AIDSStavudine treatmentCD4 countHIV infectionInhibitor useCombination therapyUnadjusted analysesObservational studyHIV-1U.S. cohortHazards modelPatientsZidovudineStavudineNew casesNRTIsProgression